title: Primary and secondary stroke prevention in nonrheumatic atrial fibrillation by oral anticoagulation.
abstract: The risk of stroke or embolism in atrial fibrillation (AF) patients can be reduced by 68% by oral anticoagulation (OAC). This review is aimed to (1) summarize indications for OAC in patients with AF, (2) give an overview of the current knowledge of risk factors for bleeding complications of OAC and (3) give practical recommendations for an optimal OAC therapy in the neurological setting. Indications for OAC are increased age (>75 years), arterial hypertension, diabetes mellitus, previous thromboembolism, heart failure and, probably, coronary heart disease. Risk factors for bleeding complications are overanticoagulation with international normalized ratios (INRs) >3.0, increased age, arterial hypertension, diabetes mellitus, previous thromboembolism, polypharmacy, the early phase of OAC therapy and a lack of patients' education. Before initiation of OAC, the patient should be screened for potential bleeding sites. Careful monitoring of OAC comprises fixed appointments for the INR value determination, tracking for the patient, if he does not attend, advices about pain therapy, information about the influence of diet on the INR value and drug interaction, unscheduled INR determination in case of acute disorders and regular assessment if OAC is still indicated. Monitoring of OAC needs an effort, which has to be adequately estimated by the health care system.
authors.affiliation: 2nd Medical Department, Krankenanstalt Rudolfstiftung, Vienna, Austria. claudia.stoellberger@chello.at
authors.forename: Claudia
authors.initials: C
authors.lastname: Stöllberger
authors.forename: Josef
authors.initials: J
authors.lastname: Finsterer
mesh_terms: D000284:Administration, Oral; D000367:Age Factors; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications*; D000075202:Contraindications; D048909:Diabetes Complications; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004617:Embolism / Q000209:etiology / Q000517:prevention & control; D006333:Heart Failure / Q000150:complications; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D006973:Hypertension / Q000150:complications; D011322:Primary Prevention / Q000379:methods; D012307:Risk Factors; D020521:Stroke / Q000209:etiology* / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants